Corneal Changes From Antibody-Drug Conjugates

Lauren A Dalvin^{1

2}, Meghan K Berkenstock³, Neel D Pasricha^{4

5}

Affiliations

¹ Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
² Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
³ The Wilmer Eye Institute, Ocular Immunology Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁴ Department of Ophthalmology, University of California, San Francisco.
⁵ Francis I. Proctor Foundation, University of California, San Francisco.

Comment

Lauren A Dalvin et al. JAMA Ophthalmol. 2025.

. 2025 Jun 1;143(6):515-516.

doi: 10.1001/jamaophthalmol.2025.1135.

Lauren A Dalvin^{1

2}, Meghan K Berkenstock³, Neel D Pasricha^{4

5}

¹ Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
² Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
³ The Wilmer Eye Institute, Ocular Immunology Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁴ Department of Ophthalmology, University of California, San Francisco.
⁵ Francis I. Proctor Foundation, University of California, San Francisco.

No abstract available

Comment on

Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
Lee V, Hultcrantz M, Petrone S, Lewis EW, Banna H, Lichtman E, Thulasi P, Quick AA, Jeng BH, Sunshine SB, Francis JH, Canestraro J, Farooq AV, Clements P, Robertson N, Burman M, McKevitt T, Struemper H, Weir L. Lee V, et al. JAMA Ophthalmol. 2025 Jun 1;143(6):507-514. doi: 10.1001/jamaophthalmol.2025.1008. JAMA Ophthalmol. 2025. PMID: 40338596 Free PMC article. Clinical Trial.